Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA

Travere Therapeutics, Inc.

2022-Q3 EPS reported -$3.34 revenue$156,150,000

Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).
Net product sales $50.8M, down from $54.2M; total revenue $53.5M.
FDA set new PDUFA date Feb 17, 2023 for sparsentan in IgAN after REMS update.
EMA accepted CMA application for sparsentan in IgAN; decision expected H2 2023.
Cash, equivalents & marketable securities $506.3M; DUPLEX FSGS data expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On October 27, 2022, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-22-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.